Incyte Corp at Goldman Sachs Healthcare Conference Transcript
Good morning, everyone. Thank you for joining us. It's my pleasure to introduce the Incyte management team. With me, I have Bill Meury, CEO; and Pablo Cagnoni, President and Global Head of R&D.
Questions & Answers
To start here, Bill, could you give us an overview of where the company stands today, including your core franchises, Jakafi and Opzelura? The pipeline priorities and just how you're thinking about, big question. But outlook and strategy for the company as we look to the next three years?
Sure. I mean, big picture, we're transitioning Incyte from a single cornerstone product to what we believe will be a portfolio of growth drivers. We think about the business across three dimensions, as you know, hematology, oncology and immunology. We also break the business down into three parts: a core business, a pipeline and then, of
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
